Bedaquiline plus delamanid for XDR tuberculosis

We read with interest the correspondence by Caitlin Reed and colleagues, reporting a patient with a severe case of extensively drug-resistant (XDR) tuberculosis who was treated with bedaquiline and subsequently denied delamanid because of concerns over additive cardiac toxic effects.1 Here we report the case of a man with XDR tuberculosis who was treated with a regimen containing bedaquiline and delamanid in combination.

A 20-year-old man from Democratic Republic of the Congo was diagnosed with pulmonary tuberculosis in October, 2014. Sputum smears were positive. Cultures confirmed an XDR Mycobacterium tuberculosis strain. On the basis of genotypic and phenotypic drug susceptibility testing, an individualised combination of ethambutol, para-aminosalicylic acid, linezolid, cyclerosine, ethionamide, and bedaquiline was initiated with directly observed treatment. After some initial improvement, the patient showed clinical and radiological worsening. In March, 2015, after the consilium organised by the French National Reference Center for Mycobacteria, a pulmonary lobectomy was done and the patient was initiated on a new tuberculosis treatment regimen under close medical supervision: ethambutol, para-aminosalicylic acid, linezolid, and bedaquiline to which delamanid, imipenem, and amoxicillin plus clavulanic acid were added. Serum potassium, calcium, magnesium, and albumin were measured before treatment initiation. An electrocardiography was done before treatment, and repeated twice a week during the first month, once a week for 2 months, and twice a month thereafter. After 6 months of treatment the patient had favourable clinical, microbiological, and radiological responses. No QT interval prolongation was observed. No other known adverse events were reported except nausea.

This is, to our knowledge, the first patient with XDR tuberculosis in whom a bedaquiline-delamanid combination has been initiated. The combination was initiated in a patient in whom an effective treatment cannot be designed, in the consideration that its potential life-saving benefits outweigh its unknown adverse event risks; in a department in which more than 100 tuberculosis cases a year are admitted to hospital, of which 14 cases are multidrug-resistant or XDR disease; after a multicentric consultation at the national level; and after patient’s informed consent. Conditions for this combination use described by Alberto Matteelli and colleagues were therefore fulfilled. Moreover, this combination was initiated under close cardiac monitoring and was well tolerated over a 6 month period. These data need to be confirmed in a larger number of patients and ideally in clinical trials. In the meantime, from an individual and societal perspective, compassionate use of these combinations should not be denied to specific patients if conditions such as those enumerated by Matteelli and colleagues are respected.

NV has received grants from Janssen, outside the submitted work. YY has received personal fees from AbbVie, Bristol-Myers Squibb, Gilead, MSD, Roche, Johnson & Johnson, ViV Healthcare, Pfizer, and Janssen for board membership, and for payment for development of educational presentation outside the submitted work. All other authors declare no competing interests.

*Marie Lachâtre, Christophe Rioux, Damien Le Dû, Mathilde Fréchet-Jachym, Nicolas Veziris, Elisabeth Bouvet, Yazdan Yazdanpanah
Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, 75018 Paris, France (ML, CR, EB, YY); Université Paris Diderot, Sorbonne Paris Cité, Paris, France (ML, EB, YY); Service de Médecine et Maladies Infectieuses, Hôpital de Bpigny, Briis sous Forges, France (DDL, MF-J); Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France (NV); Sorbonne Universités, UPMC Université Paris 06, UMR5113, Centre d’Immunologie et des Maladies Infectieuses, CMI-Paris, Team 13 (Bacteriology), Paris, France (NV); INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, CMI-Paris, Team 13 (Bacteriology), Paris, France (NV); and INSERM, IAME, UMR 1132, Paris, France (YY)


Diagnostic strategies for Ebola virus detection

Mobile laboratories for highly dangerous pathogens were deployed in west Africa during the 2014–16 outbreak of Ebola virus disease. These laboratories have substantially reduced the burden on medical professionals by providing on-site diagnostics.1 One study estimated that if 60% of patients with Ebola virus disease are diagnosed within 1 day of symptom onset, instead of the current average of 5 days, the virus attack rate drops from 80% to nearly 0%.2 This finding emphasises the substantial effect of a rapid, accurate, clinical diagnosis of Ebola virus disease supported by laboratory tests. Several diagnostic assays were authorised by the US Food and Drug Administration (FDA) for emergency use during the outbreak (appendix). Here, we analyse the use of the three kits that were also approved by WHO (table): RealStar Filovirus Screen RT-PCR Kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany),3 ReEBOV Antigen Rapid Test Kit (Corgenix, Broomfield, CO, USA),3 and Xpert Ebola Assay (Cepheid AB, Sunnyvale, CA, USA).5

The RealStar device is a real-time quantitative PCR (RT-qPCR) test for detecting the L gene. The device takes 4–6 h to provide a negative result, roughly 2 h for a positive result, and
has a limit of detection of 1 plaque-forming unit per mL, or about 3400 copies per mL. ReEBOV is a rapid chromatographic immunoassay against VP40; it takes 15–25 min to produce a final result and has a limit of detection of 2.11 × 10^8 copies per mL (extrapolation), or 1 × 10^9 plaque-forming units per mL (FDA calculated). The Xpert Ebola Assay is an RT-qPCR test for detecting viral nucleoprotein and glycoprotein. The assay takes 90 min to produce results and has a limit of detection of 82.0 RNA copies per reaction. The ReEBOV test was used in two clinics in Sierra Leone during the Ebola outbreak and was found to be 100% specific for Ebola. \(^7\) Cycle threshold values of the tested patients ranged from 15.9 to 26.3 (mean 22.6). \(^7\) However, at these values, most patients will be showing clinical signs of moderate to severe Ebola virus disease, and values less than 20 are associated with terminal disease.

Rapid diagnostic tests are also important for detecting and confirming infected patients who have not yet progressed to advanced disease (cycle threshold >30), at a time when they are less infectious to others, and with a greater chance of survival with clinical intervention. The high limit of detection suggests that the ReEBOV test is currently not sufficiently sensitive to optimally inform and manage suspect cases or outbreaks. Rather, in view of the quick turnaround time, the test is more applicable for rapid screening of patients with advanced disease, in whom a positive result would raise the alarm and push for confirmation by RT-qPCR and next-generation sequencing. RT-qPCR-based assays have a lower limit of detection; however, the longer turnaround time plus the time needed for viral RNA extraction suggests that the RealStar test and the Xpert Ebola Assay are better suited to confirmation or diagnosis of suspected cases early after onset of Ebola virus disease. Future research efforts should prioritise lowering the limit of detection of assays based on RT-qPCR to improve diagnostics for Ebola and detect and manage potential outbreaks at the earliest opportunity.

This report was partly supported by the National Key Program for Infectious Disease of China (2016ZX10004-001), the National Key Technology R&D Program of China (2015BAD12B00), the National Natural Science Foundation of China (81590760), the Priority Academic Program Development of Jiangsu Higher Education (81590760), the National Key Program for Infectious Disease of China (2015ZX10004-001), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Special Foundation of President for Ebola virus research from Chinese Academy of Sciences. GW is the recipient of a Banling Postdoctoral Fellowship from the Canadian Institutes of Health Research and the President’s International Fellowship Initiative from the Chinese Academy of Sciences. We declare no competing interests.

**Shuo Su, Gary Wong, Xiangguo Qiu, Gary Kobinger,** “Yuhai Bi,” **Jiyong Zhou jyzhou@njau.edu.cn or beeyh@im.ac.cn**

Jiangsu Engineering Laboratory of Animal Immunology, Institute of Immunology and College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China (SS, JZ), Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen, China (GW, YB); Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada (GW, XO, GK); CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China (GW, YB); and Key Laboratory of Animal Virology of Ministry of Agriculture, College of Animal Sciences and Collaborative Innovation Center and State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, China (JZ)

---

**Table:** Assays for detecting filovirus infections approved for emergency use by the US FDA and WHO

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Detection technique</th>
<th>Viruses detected</th>
<th>Target viral gene</th>
<th>Time to results</th>
<th>Limit of detection</th>
<th>Patient specimen needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>RealStar Filovirus Screen RT-PCR Kit 1.0 (Nov 2014)</td>
<td>Altona Diagnostics GmbH</td>
<td>RT-qPCR</td>
<td>Ebola virus, Sudan virus, Reston virus, Tai Forest virus, Bundibugyo virus, Marburg virus</td>
<td>L</td>
<td>4–6 h (negative), less for a positive</td>
<td>1 plaque-forming unit (about 3400 copies) of Ebola virus or Sudan virus per mL plasma</td>
</tr>
<tr>
<td>ReEBOV Antigen Rapid Test (Feb 2015)</td>
<td>Corgenix Rapid chromatogetic immunoassay</td>
<td>Ebola virus</td>
<td>VP40</td>
<td>15–25 min</td>
<td>2.11 × 10^8 RNA copies per mL (extrapolation), or 1 × 10^9 plaque-forming units per mL (FDA calculated)</td>
<td>Finger-prick (capillary) whole blood, venous whole blood, or plasma collected in EDTA</td>
</tr>
<tr>
<td>Xpert Ebola Assay (May 2015)</td>
<td>Cepheid All</td>
<td>RT-qPCR</td>
<td>Ebola virus</td>
<td>90 min</td>
<td>82.0 RNA copies per reaction (95% CI 39.7–3103.6)</td>
<td>Venous whole blood collected in EDTA</td>
</tr>
</tbody>
</table>

FDA=Food and Drug Administration.

---